This study provides evidence that the NUTM2A‐AS1/miR‐376a/TET1/PD‐L1 axis plays a key role in GC tumorigenesis and suggests that combining conventional chemotherapy with immunotherapy could yield superior treatment outcomes. The gene discussed is TET1; the disease is gastric cancer.